ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+23.97%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$71.6M
AUM Growth
+$71.6M
(-17%)
Cap. Flow
-$32.6M
Cap. Flow
% of AUM
-45.45%
Top 10 Holdings %
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$2.62M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$1.77M |
| 3 |
Taysha Gene Therapies
TSHA
|
$1.12M |
| 4 |
Akero Therapeutics
AKRO
|
$1.06M |
| 5 |
Terns Pharmaceuticals
TERN
|
$516K |
Top Sells
| 1 |
Unicycive Therapeutics
UNCY
|
$10.9M |
| 2 |
Insmed
INSM
|
$6.94M |
| 3 |
Enliven Therapeutics
ELVN
|
$5.22M |
| 4 |
Tourmaline Bio
TRML
|
$2.29M |
| 5 |
Merck
MRK
|
$2.06M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RAPP
26
Rapport Therapeutics
RAPP
$643M
| $227K | 0.32% | 20,000 +3,600 | +22% | +$40.9K |
|
|
ARTV
27
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $68.6K | 0.1% | 45,456 | – | – |
|
28
Nuvation Bio Inc. Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
NUVB.WS
$68M
| $24.5K | 0.03% | 90,832 | – | – |
|
|
29
Enliven Therapeutics
ELVN
$1.2B
| – | – | -265,269 | Closed | -$5.22M |
|
30
Edgewise Therapeutics
EWTX
$1.51B
| – | – | -85,454 | Closed | -$1.88M |
|
31
Forte Biosciences
FBRX
$137M
| – | – | -18,469 | Closed | -$143K |
|
32
Gilead Sciences
GILD
$140B
| – | – | -9,298 | Closed | -$1.04M |
|
|
MREO
33
Mereo BioPharma
MREO
$272M
| – | – | -791,815 | Closed | -$1.78M |
|
|
34
Merck
MRK
$210B
| – | – | -22,994 | Closed | -$2.06M |
|
35
Rocket Pharmaceuticals
RCKT
$354M
| – | – | -83,350 | Closed | -$556K |
|
|
VERV
36
DELISTED
Verve Therapeutics
VERV
| – | – | -162,724 | Closed | -$744K |
|